Radiology

EMulate Therapeutics Announces the Publication of the Evaluation of Its Ultra-Low Radiofrequency Energy Device in Murine Model of Glioblastoma in BMC Bioelectric Medicine

Retrieved on: 
Thursday, April 11, 2024
Research, Mental Health, Medical Devices, Neurology, Clinical Trials, Health Technology, Radiology, Health, Science, Oncology, FDA, Paclitaxel, Mouse, A1A, Ultra, GBM, DIPG, Human, Patient, A2, Paper, Emulate, Therapy, DMG

EMulate Therapeutics, Inc. (EMulate) announces the peer-reviewed publication titled, “Evaluation of the EMulate Therapeutics’ Ultra-Low Radiofrequency Energy (ulRFE®) Device in Murine Model of Glioblastoma (GBM)” in BMC Bioelectronic Medicine .

Key Points: 
  • EMulate Therapeutics, Inc. (EMulate) announces the peer-reviewed publication titled, “Evaluation of the EMulate Therapeutics’ Ultra-Low Radiofrequency Energy (ulRFE®) Device in Murine Model of Glioblastoma (GBM)” in BMC Bioelectronic Medicine .
  • The authors of the paper (Rajesh Mukthavaram; Pengfei Jiang; Sandra Pastorino; Natsuko Nomura; Feng Lin; Santosh Kesari) tested the effectiveness of the emulation of EMulate’s ulRFE signal of paclitaxel (A1A) and the immune checkpoint inhibitor ulRFE signal targeting immune checkpoints CTLA-4 and PD-1 (A2) in a murine GBM model.
  • “These data are encouraging as they demonstrate the effects we have measured and observed in human feasibility trials (NCT02296580 and NCT02507102) and other pre-clinical studies in glioblastoma models,” said Chris Rivera, EMulate’s CEO.
  • We are planning to initiate a pivotal Phase III study in these indications in 2024.”

GE HealthCare to feature Mobile Mammography Screening Truck along with Latest AI Platform as part of SBI2024 Breast Cancer Imaging Showcase

Retrieved on: 
Friday, April 12, 2024
Other Consumer, Women, Other Health, Photography, Radiology, Oncology, Software, Artificial Intelligence, Medical Devices, Hospitals, Electronic Design Automation, Consumer, Technology, General Health, Biotechnology, Health, Apps, Applications, Health Technology, FDA, Cancer, Boston Medical Center, CME, GE HealthCare, Woman, Publication, Malignancy, SBI, Breast cancer, Workplace, Research, Pathology, Artificial intelligence, DBT, CEM, Patient, Biopsy, Diagnosis, Self-assessment, Breast, Medical imaging

GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024.
  • This year’s showcase will feature the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite* and Pristina Bright** offering to demonstrate the company’s personalized approach to transforming breast cancer imaging.
  • The truck is equipped with the Senographe Pristina and Invenia ABUS to ensure accurate and efficient screenings.
  • *MyBreastAI suite is a commercial offering that includes GE HealthCare’s Edison Health Services platform, ProFound AI® for DBT, SecondLook for 2D Mammography and PowerLook® Density Assessment.

NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials

Retrieved on: 
Wednesday, April 10, 2024
Research, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Radiopharmaceutical, CDMO, Prostate cancer, Cancer, Clinical trial, Patient, Olaf Scholz, Calendar, NorthStar, Pharmaceutical industry

NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the signing of a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials.

Key Points: 
  • NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the signing of a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials.
  • The overarching Master Service agreement and associated Clinical Supply Agreement are effective immediately and the initial production of supply to support Clarity trials is expected to occur before the end of calendar 2024.
  • “Given Clarity’s outstanding clinical trial data to date, NorthStar is very excited to play a pivotal role in securing the supply of Cu-67 and final drug product for the trials with 67Cu-SAR-bisPSMA in prostate cancer,” said Frank Scholz, President and Chief Executive Officer of NorthStar.
  • “We are building out our contract development and manufacturing (CDMO) capabilities so that the biopharma innovators like Clarity can focus on discovering the next breakthrough.

Antech’s Breakthrough AI-powered Radiology and Targeted Cancer Screening Tools Now Available, Unleashing New Chapter for Veterinary Diagnostics

Retrieved on: 
Friday, April 12, 2024
Veterinary, Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Medical Devices, Technology, Veterinarian, Disease, EDTA, Lymphoma, DVM, VCA Animal Hospitals, Machine learning, Volition, Hemangiosarcoma, Diagnosis, AIS, Dog, Lifting, Cancer, Veil, Plasma, Element, Medical imaging

Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the availability of two new breakthrough innovations to mark a new chapter for veterinary diagnostics.

Key Points: 
  • Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the availability of two new breakthrough innovations to mark a new chapter for veterinary diagnostics.
  • The webinar will be offered May 21 and 22, and veterinary professionals can sign up here on Antech’s website.
  • Also now available is Nu.Q® Canine Cancer Test, a rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs.
  • Nu.Q® cancer detection includes prevalent types of canine cancers enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.

German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines

Retrieved on: 
Thursday, April 11, 2024
Research, Medical Devices, Hospitals, FDA, Genetics, Radiology, Health, Science, Oncology, Other Science, Blueprint, Woman, AGO, Breast, MD, Doctor of Philosophy, Pathology, Clinic, Gynaecology, Patient, Physician, Diagnosis, Standard of care, Radiation, Neoplasm, Breast cancer, Medical imaging

Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines.

Key Points: 
  • Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines.
  • Agendia’s MammaPrint® was added to the AGO guidelines in 2017, with level 1B medical evidence for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer.
  • MammaPrint was also added to the list of prognostic and predictive factors for extended endocrine therapy in the 2023 AGO guidelines.
  • AGO is a joint expert group consisting of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology, radiologic diagnostics, medical oncology and radiation oncology.

MedQuest Names Aalpen Patel Chief Clinical and Innovation Officer

Retrieved on: 
Wednesday, April 10, 2024
General Health, Medical Devices, Other Health, Health, Health Technology, Society, University, Biomedical engineering, Bucknell University, Rutgers University, Informatics, AI, Teaching, Stevens Institute of Technology, Machine learning, Geisinger, MD Anderson Cancer Center, Human, Intelligence, Temple University Hospital, Engineering, Radiology, Patient, Physician, Medicine, Multimedia, Student, Interventional radiology, IBM, Nursing

MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities in the U.S., has selected Dr. Aalpen Patel as Chief Clinical and Innovation Officer.

Key Points: 
  • MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities in the U.S., has selected Dr. Aalpen Patel as Chief Clinical and Innovation Officer.
  • Dr. Patel joined on March 18 in a new role overseeing all functions related to clinical practices and innovation in product development and care delivery.
  • View the full release here: https://www.businesswire.com/news/home/20240408798629/en/
    MedQuest, a leading owner, operator, and manager of outpatient diagnostic imaging facilities in the U.S., has selected Dr. Aalpen Patel as Chief Clinical and Innovation Officer.
  • “MedQuest is committed to elevating the level of service we deliver to patients, physicians, and healthcare systems across the country.

NYC Occult Inguinal Hernia Specialist Dr. Mark Zoland Shines at 2024 Endometriosis Summit

Retrieved on: 
Thursday, April 25, 2024
Pelvis, Groin, Therapy, Abdomen, Radiology, Hernia, NFL, Suite, MLS, Surgeon, Endometriosis, NBA, Patient, Coccydynia, MLB, MRI, NHL, Multimedia

NEW YORK, April 25, 2024 /PRNewswire-PRWeb/ -- The Endometriosis Summit, recently held on March 8th, 2024, in Orlando, FL, drew medical professionals, surgeons, physical therapists and patients from around the world. Renowned for his expertise in diagnosing and understanding occult hernias in the abdomen and pelvis, Dr. Mark Zoland's lecture was met with praise from attendees. It focused on the intricate nature of diagnosing occult hernias when traditional radiologists and doctors are unable to do so. His groundbreaking insights shed light on this often-overlooked condition, providing invaluable knowledge to the medical community. The 2024 Endometriosis Summit boasted an impressive lineup of interactive workshops, lab training and research-based panels. The topics covered ranged from gaslighting, treatments and tailbone pain to the intriguing world of the microbiome. Attendees also had the opportunity to participate in video sessions, surgical didactics and the highly anticipated patient and practitioner town meeting. This year, the summit introduced a groundbreaking addition to its program - a live-time imaging lab on the latest techniques in MRI and ultrasound for endometriosis. This cutting-edge feature allowed medical professionals to stay at the forefront of the field, ensuring the highest quality of care for patients.

Key Points: 
  • Esteemed specialist, Dr. Mark Zoland, recently captivated audiences as a guest speaker at the highly anticipated 2024 Endometriosis Summit.
  • Renowned for his expertise in diagnosing and understanding occult hernias in the abdomen and pelvis, Dr. Mark Zoland 's lecture was met with praise from attendees.
  • "It was an honor to be part of the 2024 Endometriosis Summit and share my expertise on occult hernias.
  • "It was an honor to be part of the 2024 Endometriosis Summit and share my expertise on occult hernias.

NashBio and CuriMeta Collaborate to Expand and Diversify Advanced Real-World Health Datasets

Retrieved on: 
Thursday, April 25, 2024
Genomics, AUC, Vanderbilt University, EMR, Research, Pathology, Disease, Radiology, DNA, Therapy, Science, RWD, Medicine, Vanderbilt University Medical Center, Organization, Pharmaceutical industry

ST. LOUIS, April 25, 2024 /PRNewswire/ -- CuriMeta, a leading expert in life science-focused, advanced real-world health data, and NashBio, a leading real-world, multi-omics data company, today announced a data licensing agreement that will bring together each organizations' distinct expertise in real-world data (RWD).

Key Points: 
  • NashBio provides real-world clinical, genomic and imaging data to their healthcare and life science research partners through their biobank, BioVU®.
  • This advanced RWD helps advance novel discoveries and the development of new, more personalized therapeutics and diagnostics.
  • "At NashBio, we say smarter data is in our DNA", said Leeland Ekstrom, founder and CEO, NashBio.
  • "Strategic collaborations with organizations like CuriMeta enhance our datasets and biobank, bringing broader, more diverse datasets to our clients.

4 university colleges in Denmark join forces to enhance on-site and remote education for radiographers with Sectra Education Portal

Retrieved on: 
Thursday, April 25, 2024
International, Learning, UNC, Elective surgery, University, University college, Medical education, Anatomy, Traumatology, Radiology, Faculty, Diagnosis, Health, UCL, Student, Nursing

LINKÖPING, Sweden, April 25, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark.

Key Points: 
  • LINKÖPING, Sweden, April 25, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark.
  • The four university colleges adopting Sectra's platform for medical education are University College Nordjylland (UNC), University College (UCL), Københavns Professionshøjskole (KP) and Professionshøjskolen Absalon.
  • By transferring to the education portal, we look forward to greatly enhancing the learning experience for our radiographer students.
  • The Sectra Education Portal is a subscription-based Software-as-a-Service solution that provides visualization tools and content at the university, at home or at the hospital.

Cortechs.ai Announces Major FDA 510(k)-Pending Update to NeuroQuant Software, Expanding Capabilities in Neuroimaging

Retrieved on: 
Wednesday, April 24, 2024
Nate White, DSM-IV codes, FDA, Health, Radiology, Patient, SAN, Neurology, AI

SAN DIEGO, April 24, 2024 /PRNewswire/ -- Cortechs.ai, a pioneer in AI-driven healthcare solutions, proudly announces a major update for its flagship product, NeuroQuant® v5.0, which is currently FDA 510(k) pending.

Key Points: 
  • SAN DIEGO, April 24, 2024 /PRNewswire/ -- Cortechs.ai, a pioneer in AI-driven healthcare solutions, proudly announces a major update for its flagship product, NeuroQuant® v5.0, which is currently FDA 510(k) pending.
  • This cutting-edge advancement marks a milestone in the field of neuroimaging AI, empowering healthcare professionals with unparalleled precision in diagnosing and monitoring neurological disorders.
  • "Our upcoming NeuroQuant® v5.0 application empowers healthcare professionals with precise data to inform diagnoses and monitor brain health.
  • The release of NeuroQuant® v5.0 strengthens our commitment to staying ahead of the curve and continuously pushing boundaries to provide AI-driven solutions to optimize patient care."